Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a ...

The Board of Directors proposes to the Annual General Meeting that no dividend be distributed based on the financial statements to be adopted for the financial year ended 31 December 2024. The Board ...

The Board of Directors proposes to the Annual General Meeting that the Annual General Meeting authorizes the Board of Directors to decide upon the repurchase of the Company's own shares and/or on the ...

Standardized documentation of surgical decision-making and preoperative surgical care may reduce Medicare audit requests for ...

London, 6 March – In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, BP p.l.c. announces that on March 6, 2025 it filed with the Securities and Exchange Commission ...